Tüdőrák: vizsgálatok itt: Spanyolország
275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- 3. fázisFut, nem toborozStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Barcelona, Madrid, Majadahonda, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - 1/2. fázisTaking peopleA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 366 worldwide
- Run by
- Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01 - 4. fázisTaking peoplePralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
- Where
- Logroño, Madrid
- Életkor
- 18 év and over
- People
- 12
- Run by
- Rigel Pharmaceuticals
See details and how to joinNCT07704658 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Barcelona, Córdoba, Jaén, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - 1. fázisTaking peopleStudy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 307 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT05433142 · EU 2024-513619-28-00 - 1. fázisTaking peopleAMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 434 worldwide
- Run by
- Amgen
See details and how to joinNCT07094113 - 1. fázisTaking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Barcelona, Madrid
- Életkor
- 18 év to 100 év
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - 3. fázisTaking peoplePhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Where
- A Coruña, Barcelona, Jaén, Madrid, San Sebastián, Zaragoza
- Életkor
- 18 év and over
- People
- 756 worldwide
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06095583 - 2. fázisTaking peoplePhase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419/ANV600) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
- Where
- Barcelona
- Életkor
- 18 év and over
- People
- 24 worldwide
- Run by
- Vall D Hebron Institute Of Oncology
See details and how to join2023-506400-99-00 - 2. fázisTaking peopleDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Barcelona, Madrid, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - 1. fázisTaking peopleClinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- Where
- Badalona, Barcelona, Madrid, Santiago de Compostela, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT05142189 · EU 2023-509283-14-00 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - 1. fázisTaking peopleA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00 - 1. fázisTaking peopleA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 710 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00 - 1. fázisNot yet taking people in SpanyolországA Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Where
- Barcelona, Madrid, Pamplona
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06476808 · EU 2025-523067-38-01 - 3. fázisTaking peopleA Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
- Where
- A Coruña, Barcelona, Donostia, Jaén, Madrid, Málaga, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01 - 1/2. fázisNot yet taking people in SpanyolországA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Where
- Badalona, Barcelona, Logroño, Madrid, Pamplona, Pozuelo de Alarcón, Sevilla
- Életkor
- 18 év and over
- People
- 262 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07174583 · EU 2025-523438-24-00 - 2. fázisTaking peopleStudy of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
- Where
- Albacete, Alicante, Barcelona, Bilbao, Elche, Jerez de la Frontera, Lugo, Madrid, Majadahonda, Málaga, Manresa, Ourense, Palma, Pamplona, Santa Cruz de Tenerife, Valencia
- Életkor
- 18 év and over
- People
- 37
- Run by
- Fundación GECP
See details and how to joinNCT07242547 · EU 2024-515201-26-00 - 1. fázisTaking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Barcelona, Elche, Jerez de la Frontera, Madrid, Málaga, Santander
- Életkor
- 18 év and over
- People
- 1006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - 1/2. fázisTaking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - 2. fázisFut, nem toborozAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Where
- A Coruña, Barcelona, Castello De La Plana, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Sevilla, Valencia
- Életkor
- 18 év to 70 év
- People
- 170 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00 - 1. fázisTaking peopleSubcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Where
- Barcelona, Madrid, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06598306 · EU 2024-511838-12-00 - 1. fázisTaking peopleA Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 52
- Run by
- Janssen Cilag International
See details and how to join2025-521535-36-00 - 1/2. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Badalona, Barcelona, Valencia
- Életkor
- 18 év and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - 1. fázisTaking peopleStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Where
- L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 248 worldwide
- Run by
- Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00